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PreviewsFuture investigations, making use of
modern molecular tools and taking
advantage of the genetic diversity of
LPBN, must contribute to further dissect
the circuitry underlying the multiple phys-
iological roles of this pontine nucleus
whose integrity is critical for survival.REFERENCES
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Disruptions in cholesterol homeostasis contribute to cardiovascular disease (CVD). In a recent issue of Cell
Metabolism, Demetz et al. (2014) report that endogenous lipoxygenase-mediated metabolism of another
lipid, arachidonic acid, produces lipoxins that regulate reverse cholesterol transport. These results suggest
that lipoxins may represent a novel class of therapeutics for CVD.Myocardial infarction and stroke are the
primary clinical manifestations of athero-
sclerosis, a pathology associated with
accumulation of cholesterol and inflam-
matory cells in the vasculature. An
imbalance in the production, tissue de-
livery, and removal of cholesterol is a
key underlying factor in the develop-
ment of atherosclerosis because subinti-
mal accumulation of low-density lipo-
protein-associated cholesterol (LDL-C)
renders it susceptible to oxidative modi-
fication and promotes a robust immune
response (Libby et al., 2014). Immune
cells, including macrophages, are re-
cruited to sites of cholesterol deposition
in a maladaptive response that ulti-
mately leads to the formation of a
detritus lesion prone to rupture and sub-
sequent thrombosis (Libby et al., 2014).
However, macrophages also play a
role in reverse cholesterol transport
(RCT), a process in which transfer of
cholesterol to high-density lipoprotein(HDL) enables the return of excess
cholesterol to the liver for excretion in
the form of bile acids (Rosenson et al.,
2012). As such, delineation of factors
that enhance RCT has potential to lead
to the development of novel therapeu-
tics for CVD.
In a recent issue of Cell Metabolism,
Demetz et al. (2014) identify lipid media-
tors generated from omega-6 polyunsat-
urated fatty acid (PUFA), arachidonic
acid (AA), as novel regulators of RCT.
Analogous to the ‘‘good cholesterol:
bad cholesterol’’ classification of HDL
and LDL, respectively, PUFA are gener-
ally regarded as being beneficial for
CVD, whereas saturated fats have nega-
tive associations with CVD. The work by
Demetz et al. (2014) highlights a potential
mechanism underlying the beneficial ef-
fects of PUFA in this regard. Starting
from analysis of previous genome-wide
association studies (GWASs), Demetz
et al. (2014) uncover arachidonate 5-lip-oxygenase (ALOX5) SNPs that are
related to HDL-C levels and function in
humans. This suggests that AA-derived
mediators may regulate cholesterol
metabolism.
To identify such products of AA meta-
bolism, Demetz et al. (2014) first used a
pharmacologic approach with aspirin to
promote shunting of AA from cyclooxy-
genase (COX) to lipoxygenase (LOX)
pathways. In these experiments, aspirin
was administered to mice and RCT was
monitored by following the distribution
of radiolabeled [3H]-cholesterol in the
plasma, bile, and feces. This analysis
demonstrated that aspirin decreased
accumulation of [3H]-cholesterol in the
plasma, while it enhanced the appear-
ance of [3H]-sterols in the bile and feces,
suggesting increased RCT. Mechanisti-
cally, aspirin treatment enhanced bile
acid transport via the ATP-binding
cassette subfamily B member 11
(Abcb11; also known as bile salt exportDecember 2, 2014 ª2014 Elsevier Inc. 935
Figure 1. Regulation of Cholesterol Metabolism by Lipid Mediators
Arachidonic acid is converted to prostaglandins (PGs) by cyclooxygenase (COX) enzymes. Aspirin inhibits
the production of PGs and results in substrate diversion of AA to lipoxygenase (LOX) pathways in the liver
and also promotes the generation of 15-epimeric lipoxins. Arachidonate 5-lipoxygenase (Alox5) is involved
in the biosynthesis of leukotriene B4 (LTB4) and the lipoxins, LXA4 (5S, 6R, 15S- trihydroxy- 7E, 9E, 11Z,
13E- eicosatetraenoic acid) and LXB4 (5S, 14R, 15S- trihydroxy- 6E, 8Z, 10E, 12E- eicosatetraenoic acid).
Aspirin treatment enhances reverse cholesterol transport in part by increasing the production of Alox5-
derived mediators and subsequent bile acid secretion through ATP-binding cassette subfamily b member
11 (Abcb11). These protective actions are recapitulated by administration of stable analogs of LXB4
(i.e., 5-R/S-methyl LXB4).
Cell Metabolism
Previewspump [BSEP]). Accordingly, enhance-
ment of RCT by aspirin was lost in
Abcb11/ mice and aspirin treatment
robustly decreased atherosclerotic lesion
formation in LDLR/ mice. Mass spec-
trometry-based lipidomics profiling of
the AA metabolome in livers of aspirin-
treated mice demonstrated that, as ex-
pected, aspirin decreased the formation
of COX products including thromboxane
and prostacyclin (measured as their
stable downstream metabolites, TXB2
and 6-keto PGF1a). These changes
were accompanied by increased produc-
tion of LOX products, leukotriene B4
(LTB4) and lipoxin A4 (LXA4), suggesting
that these products may underlie the
effects of aspirin on RCT. Indeed, leuko-
trienes (LT) and lipoxins (LX) increased
expression of Abcb11 in isolated hepato-
cytes in a p38-dependent manner and
to a similar extent as aspirin, while
expression of receptors important in li-
poprotein uptake (i.e., LDL-R and scav-
enger receptor BI [SR-B1]) were not
altered.
LT and LX are families of lipid media-
tors generated by LOX enzymes that
have opposing biological actions (Sa-
muelsson et al., 1987). That is, LTB4 is936 Cell Metabolism 20, December 2, 2014 ªa proinflammatory mediator generated
by ALOX5 that recruits leukocytes to
sites of tissue injury and infection,
whereas LX are anti-inflammatory (Sa-
muelsson et al., 1987) and have emerged
as mediators that promote resolution of
acute inflammation (Spite and Serhan,
2010). Of note, LX also have direct ac-
tions on the vasculature, which include
the regulation of permeability and pro-
duction of antithrombotic and vasoactive
mediators (Brezinski et al., 1992; Spite
and Serhan, 2010). Although ALOX5 is
required for LX biosynthesis, other en-
zymes including ALOX12 and ALOX15
(ALOX15-type 1 in humans) are also
needed to form LX (see Figure 1). Inter-
estingly, aspirin-acetylation of COX2
can trigger endogenous biosynthesis
of 15R epimers of LX (coined aspirin-
triggered LX), providing an alternate
route for increased LX formation in the
presence of aspirin. Importantly, statins,
the mainstay of cholesterol-lowering
therapy, also increase the production
of epimeric LX (Spite and Serhan,
2010). Demetz et al. (2014) found that
although both LTB4 and LX increased
expression of Abcb11 in vitro, studies
using Alox5-deficient mice indicated2014 Elsevier Inc.that LX may be more important in regu-
lating RCT because loss of Alox5
decreased the LT:LX ratio with a
concomitant increase in Abcb11 levels.
Of note, Alox5 phosphorylation status is
an important determinant in the balance
of LT and LX biosynthesis, thus compli-
cating interpretation of studies from
mice globally deficient in the enzyme
(Fredman et al., 2014). Nonetheless, in
agreement with the view that LX are
important in regulating cholesterol meta-
bolism in vivo, an LXB4 analog (5-R/S-
methyl LXB4), which resists rapid local
inactivation by prostaglandin dehydroge-
nase (Maddox et al., 1998), was suffi-
cient to decrease total plasma choles-
terol in vivo. This effect was driven by
decreases in very-low-density lipoprotein
(VLDL) and LDL. However, levels of
Abcb11 were decreased in vivo by
LXB4, while LDL-R and SR-B1 were
increased. The decrease in Abcb11 in
this scenario could potentially be related
to sustained activation of this pathway,
or as the in vitro results suggest, a
dose-dependent effect involving a
compensatory decrease at high concen-
trations of LXB4. Thus, further studies are
required to interrogate fully the mecha-
nisms underlying the protective actions
of LX in cholesterol metabolism.
Overall, the study by Demetz et al.
(2014) assigns new biological roles of LX
to the regulation of cholesterol meta-
bolism. Given their potent inflammation-
resolving actions, LX may represent a
novel class of therapeutics for CVD (Ser-
han, 2014). As LX also stimulate macro-
phage phagocytosis of apoptotic cells
and regulate their trafficking, LX could
play a much broader role in the context
of atherosclerosis regression. It remains
to be determined whether LX directly
promote regression of atherosclerosis
(Merched et al., 2008) and given that
levels of epimeric LX inversely correlate
with peripheral atherosclerosis in humans
(Spite and Serhan, 2010), it will be
important to determine whether LX and
other newly identified proresolving lipid
mediators (e.g., resolvins) can ‘‘resolve’’
long-standing limitations to therapeutic
management of CVD.REFERENCES
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Obesity and the associated state of subchronic inflammation are risk factors for numerous pathologies,
including carcinogenesis. Recently, Schulz et al. (2014) demonstrated that high-fat diet-induced intestinal
dysbiosis promotes cancer development in K-rasG12Dintmice without inducing obesity or mucosal inflamma-
tion, positioning microbial activities as a central component of diet-induced carcinogenesis.The intestinal tract is a dynamic milieu
where 100 trillion bacteria interact daily
with lumenal contents, intestinal epithelial
cells, and underlying immune cells. The
interplay between these factors repre-
sents a key balance point between ho-
meostasis and disease, as aberration in
any of their activities can lead to inflam-
mation and even cancer (Irraza´bal et al.,
2014). With its impact on host and mi-
crobes, nutrition represents an important
factor able to influence the homeostatic
circuitry present in the gut. For example,
diet-induced obesity has been associ-
ated with a 30%–70% increased risk
of colon cancer in men (Bardou et al.,
2013) and is linked to an altered intestinal
microbiota (Ley et al., 2006). However, the
contribution of obesity-associated low-
grade inflammation in diet-induced carci-
nogenesis and the role of microbes in this
pathological cascade are unclear.
A recent publication by Schulz et al.
contributes an important piece to this
puzzle by demonstrating that the dys-
biosis caused by consumption of a
lard-based high-fat diet (HFD) enhances
adenocarcinoma development and
metastasis in K-rasG12Dint mice, withoutpromoting overt inflammation or causing
obesity (Schulz et al., 2014). This observa-
tion suggests that HFD-induced cancer is
not preceded by obesity or inflammation,
but rather depends on microbial activity.
The cancer-promoting microbiota seems
to depend on both the HFD and host
genetics. Indeed, the authors showed
that K-ras oncogene activation results in
decreased Paneth cell function (cryptdin
expression), while HFD attenuates mucin
expression (Muc2), two components crit-
ical in controlling intestinal microbial load
and geographical distribution. Therefore,
these changes likely act in concert to pro-
mote the progression from low-level
dysplasia in regular chow-fed mice to
small bowel carcinogenesis and metas-
tasis in mice consuming HFD.
The provocative observation that K-
rasG12Dint mice fed HFD developed can-
cer while remaining significantly leaner,
without evidence of metabolic syndrome,
challenges the dogmatic sequence of diet
inducing obesity and the subsequent
inflammation leading to cancer. Indeed,
the authors were able to transfer the
carcinogenic phenotype by fecal trans-
plants, demonstrating the primary role ofbacteria in cancer development in these
mice. However, this phenotype is only
seen in fecal-transplanted K-rasG12Dint
mice, not in transplanted LSL-K-rasG12D/
+ littermate controls, supporting the
notion that cancer arises from an interac-
tion between genes and the environment
(bacteria). Importantly, while inducing
carcinogenesis, the microbiota transfer
did not promote obesity or insulin desen-
sitization (Schulz et al., 2014). Therefore,
changes in microbial factors drive cancer
development in these mice rather than di-
etary differences, body mass index, or
low-grade intestinal inflammation. As
few models are able to dissociate these
consequences of HFD, this study pro-
vides a revelation regarding the interplay
between environment factors such as
nutrition and the path to carcinogenesis.
While there is likely still a role for direct di-
etary effects on other aspects of cancer, it
is clear that microbiota play a critical,
central role in absorbing the impact of
various dietary insults and passing the
consequences on to the host (Figure 1).
Interestingly, short-chain fatty acid pro-
duction by the microbiota was impaired in
HFD-fed K-rasG12Dint mice, and butyrateDecember 2, 2014 ª2014 Elsevier Inc. 937
